Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data from the EVEREST study

被引：2

作者：

Humblet, Y. ^{[1
]}

Peeters, M. ^{[2
]}

Gelderblom, H. ^{[3
]}

Vermorken, J. B. ^{[4
]}

Viret, F. ^{[5
]}

Glimelius, B. ^{[6
]}

Ciardiello, F. ^{[7
]}

Gallerani, E. ^{[8
]}

Kisker, O. ^{[9
]}

Van Cutsem, E. ^{[10
]}

机构：

[1] Univ St Luc, Brussels, Belgium

[2] State Univ Ghent Hosp, B-9000 Ghent, Belgium

[3] Univ Med Ctr, Leiden, Netherlands

[4] Univ Antwerp Hosp, Dept Med Oncol, Antwerp, Belgium

[5] Inst J Paoli I Calmettes, F-13009 Marseille, France

[6] Akad Univ Hosp, Uppsala, Sweden

[7] Univ Naples 2, Dipartimento Med Chirurg Internist Clin & Sperime, Naples, Italy

[8] Inst Oncol So Switzerland, Bellinzona, Switzerland

[9] MErck KG&A, R&D Med Sci Oncol, Darmstadt, Germany

[10] Univ Hosp Gasthuisberg, Dept Gastroenterol, B-3000 Louvain, Belgium

来源：

EJC SUPPLEMENTS | 2007年 / 5卷 / 04期

关键词：

D O I：

10.1016/S1359-6349(07)70945-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3017

引用

页码：240 / 240

页数：1